Curiox Biosystems（A445680）株式概要キュリオックス・バイオシステムズ社は、韓国で医療機器・器具を製造・販売している。 詳細A445680 ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間19.5%減少しました。 KR市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある収益がありません ( ₩5B )すべてのリスクチェックを見るA445680 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩82.50k15.7k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-27b7b2016201920222025202620282031Revenue ₩3.8bEarnings ₩484.6mAdvancedSet Fair ValueView all narrativesCuriox Biosystems Co., Ltd 競合他社Penetrium BioscienceSymbol: KOSDAQ:A187660Market cap: ₩446.3bPeptronSymbol: KOSDAQ:A087010Market cap: ₩5.6tFutureChemLtdSymbol: KOSDAQ:A220100Market cap: ₩349.8bCuriosisSymbol: KOSDAQ:A494120Market cap: ₩312.7b価格と性能株価の高値、安値、推移の概要Curiox Biosystems過去の株価現在の株価₩82,500.0052週高値₩149,200.0052週安値₩28,150.00ベータ2.071ヶ月の変化-6.04%3ヶ月変化-25.74%1年変化182.05%3年間の変化n/a5年間の変化n/aIPOからの変化852.11%最新ニュースNew Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩4.3b revenue, or US$2.9m).お知らせ • Feb 06Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 61, gasan-ro, geumcheon-gu, seoul South Korea分析記事 • Oct 31Is Curiox Biosystems (KOSDAQ:445680) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.9b revenue, or US$2.8m).分析記事 • Jul 16Does Curiox Biosystems (KOSDAQ:445680) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Jun 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (₩3.9b revenue, or US$2.9m).最新情報をもっと見るRecent updatesNew Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩4.3b revenue, or US$2.9m).お知らせ • Feb 06Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 61, gasan-ro, geumcheon-gu, seoul South Korea分析記事 • Oct 31Is Curiox Biosystems (KOSDAQ:445680) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.9b revenue, or US$2.8m).分析記事 • Jul 16Does Curiox Biosystems (KOSDAQ:445680) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Jun 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (₩3.9b revenue, or US$2.9m).Reported Earnings • Mar 25Full year 2024 earnings released: ₩503 loss per share (vs ₩702 loss in FY 2023)Full year 2024 results: ₩503 loss per share (improved from ₩702 loss in FY 2023). Net loss: ₩8.09b (loss narrowed 19% from FY 2023).New Risk • Feb 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (₩6.0b revenue, or US$4.1m).お知らせ • Feb 07Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2025Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Koreaお知らせ • Jan 25Curiox Biosystems Launches Curiox C- Free Pluto ALPHA: Affordable, Hassle-Free Cell Washing AutomationCuriox Biosystems announced the launch of the Curiox C- Free Pluto ALPHA, the latest addition to the Pluto line of products. This compact and intuitive device redefines cell washing automation, bringing simplicity, reliability, and affordability to labs of all sizes. The Curiox C- Free Pluto AlphaHA replaces traditional centrifuge-based methods, offering a low-main maintenance solution that eliminates bulky hardware. Utilizing a pipette head, it delivers gentle, consistent washing of suspension cells and beads, preserving sample integrity and improving reproducibility. By simplifying workflows and reducing variability, Curiox C- Free PlutoALHA helps researchers achieve more consistent, high-quality results in less time. Key Features: Gentle Washing: Pipette-based technology ensures cell viability by avoiding centrifugation, preserving deliver cells. Effortless Integration: Compact design fits seamlessly into existing workflows, with no need for additional infrastructure. Labware Compatibility: Supports 96-well plates, deep-well plates, and Laminar Wash plates, ensuring immediate adaptability to setup. Minimal Maintenance: Virtually the same as a pipetting station, reducing downtime and operational costs for labs. Affordable Automation: Priced below $30,000, it delivers cutting-edge performance within budget-friendly constraints. Compact Footprint: Its small size ensures efficient use of valuable bench space, making it ideal for labs of all sizes. Workflow Benefits: Pre-configured with Light, Moderate, Heavy, and Ultra wash protocols, the Curiox C- Free Neptune ALPHA minimizes hands-on time for researchers, allowing them to focus on high-value tasks. The elimination of centrifugation, flicking, or resuspension steps streamlines workflows while ensuring reproducibility across experiments. These features are especially valuable for immunophenotyping, cell therapy, and drug discovery applications. Emowering Labs with the Pluto Line: The Pluto product line reflects Curiox's mission to drive innovation and enhance productivity. With a focus on scalability and adaptability, Pluto devices cater to diverse research and clinical needs. Whether for small-scale studies or industrial-scale operations, Curiox C- Free Neptune AlphaHA is a critical step in advancing automated cell washing solutions. Configurations to suit Every Need: Standard Model: Equipped with a fixed 96-channel pipette head and three plate decks, it supports wash cycles from 2 minutes onwards: tailored for precision. Custom Options: Flexible throughput with configurable pipette tips and customizable wash parameters ensures adaptability for specialized workflows.分析記事 • Dec 16Curiox Biosystems (KOSDAQ:445680) Has Debt But No Earnings; Should You Worry?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).お知らせ • Jul 27Curiox Biosystems Co., Ltd announced that it has received KRW 20 billion in funding from KB Securities Co.,Ltd, LS SECURITIES Co., Ltd., JB Woori Capital Co., Ltd, Kiwoom Securities Co., Ltd., KDB Capital Corp., IBK Capital Corporation and other investorsOn July 26, 2024, Curiox Biosystems Co., Ltd closed the transaction.分析記事 • Jun 20We're Not Very Worried About Curiox Biosystems' (KOSDAQ:445680) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Apr 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (₩6.8b revenue, or US$4.9m).New Risk • Apr 11New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩6.8b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩6.8b revenue, or US$5.0m).分析記事 • Mar 04We're Interested To See How Curiox Biosystems (KOSDAQ:445680) Uses Its Cash Hoard To GrowWe can readily understand why investors are attracted to unprofitable companies. For example, although...株主還元A445680KR Life SciencesKR 市場7D-13.0%-8.2%-8.2%1Y182.1%-15.2%159.6%株主還元を見る業界別リターン: A445680過去 1 年間で-15.2 % の収益を上げたKR Life Sciences業界を上回りました。リターン対市場: A445680過去 1 年間で159.6 % の収益を上げたKR市場を上回りました。価格変動Is A445680's price volatile compared to industry and market?A445680 volatilityA445680 Average Weekly Movement17.0%Life Sciences Industry Average Movement11.0%Market Average Movement9.3%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%安定した株価: A445680の株価は、 KR市場と比較して過去 3 か月間で変動しています。時間の経過による変動: A445680の weekly volatility ( 17% ) は過去 1 年間安定していますが、依然としてKRの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2018n/aNamyong Kimwww.curiox.comキュリオックス・バイオシステムズ社は、韓国で医療機器・器具の製造・販売を行っている。高い細胞保持率と生存率を可能にする分離データを生成する層洗浄技術システムlaminar wash HT2000や、フローサイトメトリーやマスサイトメトリーの表面および細胞内染色ワークフローを完全に自動化するシステムlaminar wash auto 1000を提供している。また、遠心分離機を使用しない懸濁細胞サンプル前処理法を提供するlaminar wash miniシステム、遠心分離を不要にするlaminar washプレート、マルチプレックスイムノアッセイ用のDroparray装置、サンプル前処理を減らし、データ品質とバイオセーフティを高めるDroparrayビーズプレートも提供している。同社は2018年に法人化され、韓国・ソウルを拠点に、マサチューセッツ州ウォバーン、シンガポール、中国・上海、英国、アイルランドにも拠点を置いている。もっと見るCuriox Biosystems Co., Ltd 基礎のまとめCuriox Biosystems の収益と売上を時価総額と比較するとどうか。A445680 基礎統計学時価総額₩1.42t収益（TTM）-₩27.18b売上高(TTM)₩5.15b275.5xP/Sレシオ-52.2xPER（株価収益率A445680 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A445680 損益計算書（TTM）収益₩5.15b売上原価₩3.02b売上総利益₩2.14bその他の費用₩29.31b収益-₩27.18b直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-1.58kグロス・マージン41.45%純利益率-527.54%有利子負債／自己資本比率3.5%A445680 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 18:34終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Curiox Biosystems Co., Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩4.3b revenue, or US$2.9m).
お知らせ • Feb 06Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 61, gasan-ro, geumcheon-gu, seoul South Korea
分析記事 • Oct 31Is Curiox Biosystems (KOSDAQ:445680) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.9b revenue, or US$2.8m).
分析記事 • Jul 16Does Curiox Biosystems (KOSDAQ:445680) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Jun 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (₩3.9b revenue, or US$2.9m).
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩4.3b revenue, or US$2.9m).
お知らせ • Feb 06Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 61, gasan-ro, geumcheon-gu, seoul South Korea
分析記事 • Oct 31Is Curiox Biosystems (KOSDAQ:445680) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.9b revenue, or US$2.8m).
分析記事 • Jul 16Does Curiox Biosystems (KOSDAQ:445680) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Jun 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (₩3.9b revenue, or US$2.9m).
Reported Earnings • Mar 25Full year 2024 earnings released: ₩503 loss per share (vs ₩702 loss in FY 2023)Full year 2024 results: ₩503 loss per share (improved from ₩702 loss in FY 2023). Net loss: ₩8.09b (loss narrowed 19% from FY 2023).
New Risk • Feb 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (₩6.0b revenue, or US$4.1m).
お知らせ • Feb 07Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2025Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
お知らせ • Jan 25Curiox Biosystems Launches Curiox C- Free Pluto ALPHA: Affordable, Hassle-Free Cell Washing AutomationCuriox Biosystems announced the launch of the Curiox C- Free Pluto ALPHA, the latest addition to the Pluto line of products. This compact and intuitive device redefines cell washing automation, bringing simplicity, reliability, and affordability to labs of all sizes. The Curiox C- Free Pluto AlphaHA replaces traditional centrifuge-based methods, offering a low-main maintenance solution that eliminates bulky hardware. Utilizing a pipette head, it delivers gentle, consistent washing of suspension cells and beads, preserving sample integrity and improving reproducibility. By simplifying workflows and reducing variability, Curiox C- Free PlutoALHA helps researchers achieve more consistent, high-quality results in less time. Key Features: Gentle Washing: Pipette-based technology ensures cell viability by avoiding centrifugation, preserving deliver cells. Effortless Integration: Compact design fits seamlessly into existing workflows, with no need for additional infrastructure. Labware Compatibility: Supports 96-well plates, deep-well plates, and Laminar Wash plates, ensuring immediate adaptability to setup. Minimal Maintenance: Virtually the same as a pipetting station, reducing downtime and operational costs for labs. Affordable Automation: Priced below $30,000, it delivers cutting-edge performance within budget-friendly constraints. Compact Footprint: Its small size ensures efficient use of valuable bench space, making it ideal for labs of all sizes. Workflow Benefits: Pre-configured with Light, Moderate, Heavy, and Ultra wash protocols, the Curiox C- Free Neptune ALPHA minimizes hands-on time for researchers, allowing them to focus on high-value tasks. The elimination of centrifugation, flicking, or resuspension steps streamlines workflows while ensuring reproducibility across experiments. These features are especially valuable for immunophenotyping, cell therapy, and drug discovery applications. Emowering Labs with the Pluto Line: The Pluto product line reflects Curiox's mission to drive innovation and enhance productivity. With a focus on scalability and adaptability, Pluto devices cater to diverse research and clinical needs. Whether for small-scale studies or industrial-scale operations, Curiox C- Free Neptune AlphaHA is a critical step in advancing automated cell washing solutions. Configurations to suit Every Need: Standard Model: Equipped with a fixed 96-channel pipette head and three plate decks, it supports wash cycles from 2 minutes onwards: tailored for precision. Custom Options: Flexible throughput with configurable pipette tips and customizable wash parameters ensures adaptability for specialized workflows.
分析記事 • Dec 16Curiox Biosystems (KOSDAQ:445680) Has Debt But No Earnings; Should You Worry?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
お知らせ • Jul 27Curiox Biosystems Co., Ltd announced that it has received KRW 20 billion in funding from KB Securities Co.,Ltd, LS SECURITIES Co., Ltd., JB Woori Capital Co., Ltd, Kiwoom Securities Co., Ltd., KDB Capital Corp., IBK Capital Corporation and other investorsOn July 26, 2024, Curiox Biosystems Co., Ltd closed the transaction.
分析記事 • Jun 20We're Not Very Worried About Curiox Biosystems' (KOSDAQ:445680) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Apr 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (₩6.8b revenue, or US$4.9m).
New Risk • Apr 11New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩6.8b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩6.8b revenue, or US$5.0m).
分析記事 • Mar 04We're Interested To See How Curiox Biosystems (KOSDAQ:445680) Uses Its Cash Hoard To GrowWe can readily understand why investors are attracted to unprofitable companies. For example, although...
